Equities Analysts Set Expectations for Neurocrine Biosciences, Inc.’s FY2017 Earnings (NBIX)

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Stock analysts at Leerink Swann raised their FY2017 earnings per share (EPS) estimates for Neurocrine Biosciences in a research note issued on Sunday, according to Zacks Investment Research. Leerink Swann analyst P. Matteis now expects that the company will earn ($1.47) per share for the year, up from their prior forecast of ($1.67). Leerink Swann has a “Outperform” rating and a $83.00 price objective on the stock. Leerink Swann also issued estimates for Neurocrine Biosciences’ Q4 2017 earnings at $0.22 EPS, Q1 2018 earnings at ($0.07) EPS, Q2 2018 earnings at $0.03 EPS, Q3 2018 earnings at $0.31 EPS, Q4 2018 earnings at $0.18 EPS, FY2018 earnings at $0.46 EPS and FY2019 earnings at $2.04 EPS.

Several other equities analysts have also issued reports on the company. Jefferies Group upped their target price on Neurocrine Biosciences to $105.00 and gave the company a “buy” rating in a report on Friday, January 5th. BMO Capital Markets upped their target price on Neurocrine Biosciences from $83.00 to $109.00 and gave the company an “outperform” rating in a report on Thursday, November 2nd. Oppenheimer set a $85.00 target price on Neurocrine Biosciences and gave the company a “buy” rating in a report on Tuesday, December 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $86.00 target price on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Finally, Barclays upped their target price on Neurocrine Biosciences from $75.00 to $85.00 and gave the company an “overweight” rating in a report on Thursday, November 2nd. One investment analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Neurocrine Biosciences currently has an average rating of “Buy” and an average target price of $82.31.

Neurocrine Biosciences (NASDAQ:NBIX) traded down $2.69 during mid-day trading on Wednesday, hitting $83.33. The stock had a trading volume of 776,214 shares, compared to its average volume of 999,530. The company has a market capitalization of $7,370.00, a price-to-earnings ratio of -37.54, a PEG ratio of 14.17 and a beta of 0.26. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences has a 52 week low of $39.21 and a 52 week high of $91.82.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.36. The company had revenue of $60.77 million for the quarter, compared to the consensus estimate of $29.38 million. During the same period in the prior year, the firm posted ($0.43) earnings per share.

In related news, insider Darin Lippoldt sold 9,900 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $73.05, for a total value of $723,195.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Gary A. Lyons sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $72.92, for a total value of $729,200.00. Following the completion of the transaction, the director now owns 272,066 shares in the company, valued at approximately $19,839,052.72. The disclosure for this sale can be found here. In the last quarter, insiders sold 106,462 shares of company stock worth $8,104,607. 4.80% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of the business. CIBC Asset Management Inc purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter worth $230,000. Rockefeller Financial Services Inc. purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter worth $285,000. Aperio Group LLC lifted its position in shares of Neurocrine Biosciences by 13.9% during the fourth quarter. Aperio Group LLC now owns 24,967 shares of the company’s stock worth $1,937,000 after acquiring an additional 3,055 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Neurocrine Biosciences by 25.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,904 shares of the company’s stock worth $458,000 after acquiring an additional 1,200 shares in the last quarter. Finally, Dupont Capital Management Corp lifted its position in shares of Neurocrine Biosciences by 32.4% during the fourth quarter. Dupont Capital Management Corp now owns 95,963 shares of the company’s stock worth $7,446,000 after acquiring an additional 23,466 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: “Equities Analysts Set Expectations for Neurocrine Biosciences, Inc.’s FY2017 Earnings (NBIX)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/02/leerink-swann-brokers-lift-earnings-estimates-for-neurocrine-biosciences-inc-nbix.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply